Research Horizons
Spin-off Company Forms to Advance Potential Cancer Treatment
Post Date: May 1, 2020
Daniel Starczynowski, PhD
Seed investor CincyTech has announced the formation of Kurome Therapeutics (“Kurome”), a spin-off company based on cancer research discoveries made at Cincinnati Children’s by Daniel Starczynowski, PhD, and colleagues.
Kurome is developing combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of chemotherapy drugs by adaptive resistance, having co-opted immune signaling pathways to survive.
Read more about this line of research:
NIH, Cincinnati Children’s Scientists Develop Potential Strategy Against Leukemia Drug Resistance
Overlooked Molecular Machine in Cell Nucleus May Hold Key to Treating Aggressive Leukemia
Science Translational Medicine: Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Research Areas
- > Asthma and Allergy
- > Autoimmune Disorders
- > Big Data and Analytics
- > Cancer
- > Community Health
- > Diabetes and Obesity
- > Digestive System
- > Emergency and Critical Care
- > Genomics and Development
- > Health Inequities
- > Heart and Lung
- > Imaging Sciences
- > Infectious Diseases and Vaccines
- > Mind Brain Behavior
- > Organoids
- > Ortho, Sports Med and Rehab
- > Perinatal
- > Quality and Safety
- > Rare Diseases
- > Surgical Science
- > Tools for Science
Latest Posts
About this blog
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.